Literature DB >> 10077376

Beta-blockade versus Buckberg blood-cardioplegia in coronary bypass operation.

F Kuhn-Régnier1, E Natour, S Dhein, O Dapunt, H J Geissler, K LaRosé, C Görg, U Mehlhorn.   

Abstract

OBJECTIVE: Continuous perfusion of the coronary arteries with beta-blocker (esmolol)-enriched normothermic blood during cardiac surgery has been suggested as an alternative technique for myocardial protection. The aim of the present study was to compare the beta-blocker technique to Buckberg's blood cardioplegia during coronary artery bypass grafting (CABG).
METHODS: Sixty patients with coronary artery disease were randomly assigned to either the esmolol group (ES, n = 30) or the blood cardioplegia group (BC, n = 30). During aortic crossclamp ES patients received continuous normothermic coronary perfusion with esmolol-enriched blood. Hearts of the BC group were protected by antegrade cold blood cardioplegia according to Buckberg. We measured left ventricular (LV) contractility using TEE (fractional area of contraction, FAC) and hemodynamic parameters prior to cannulation for cardiopulmonary bypass (CPB), after decannulation, and 4 h postoperatively. Myocardial lactate release was measured prior to aortic cross-clamp, during cross-clamp, and after decannulation. LV biopsies for determination of heat-shock protein (HSP-70), actin pattern and intercellular adhesion-molecule (ICAM-I) as indicators for structural changes were collected prior CPB, at the end of the aortic cross-clamp period, and prior to weaning off CPB.
RESULTS: There was no significant difference between both groups with respect to grafts and cross-clamp time. ES hearts did not release lactate during cross-clamp. In contrast, BC hearts released significant amounts of lactate. Post CPB FAC and hemodynamics under similar inotropic stimulation showed no difference between groups, whereas at 4 h post CPB measurements showed slightly better values in the ES group: cardiac index: ES: 2.9+/-0.1 (SEM) versus BC: 2.6+/-0.1 L/min per m2 (P < 0.05); FAC: ES: 55+/-3 versus BC: 48+/-3% (P < 0.05). HSP-70 and actin pattern showed no difference between groups; however, ICAM-I showed a significantly higher degree of structural changes in BC hearts: 18+/-2 versus ES: 11+/-1% (P < 0.05).
CONCLUSION: Our data demonstrate that application of the beta-blocker technique during routine CABG was associated with slightly better functional recovery and less structural myocardial alteration as compared with intermittent cold blood cardioplegia, however, both techniques provided equivalent myocardial protection in terms of patient outcome. Future studies are required to investigate if myocardial ischemia minimization by use of the beta-blocker technique may be beneficial in compromized hearts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077376     DOI: 10.1016/s1010-7940(98)00289-9

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

Review 2.  Therapeutic hypothermia and prevention of acute kidney injury: a meta-analysis of randomized controlled trials.

Authors:  Paweena Susantitaphong; Mansour Alfayez; Abraham Cohen-Bucay; Ethan M Balk; Bertrand L Jaber
Journal:  Resuscitation       Date:  2011-10-06       Impact factor: 5.262

Review 3.  Clinical pharmacokinetics and therapeutic efficacy of esmolol.

Authors:  Donald B Wiest; Jason S Haney
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

4.  Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts.

Authors:  Kazutoshi Ikeshita; Kiyonobu Nishikawa; Sumiko Toriyama; Tomoyuki Yamashita; Yoshiyuki Tani; Tokuhiro Yamada; Akira Asada
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

5.  Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.

Authors:  Nicholas Chun; Ala S Haddadin; Junying Liu; Yunfang Hou; Karen A Wong; Daniel Lee; Julie I Rushbrook; Karan Gulaya; Roberta Hines; Tamika Hollis; Beatriz Nistal Nuno; Abeel A Mangi; Sabet Hashim; Marcela Pekna; Amy Catalfamo; Hsiao-Ying Chin; Foramben Patel; Sravani Rayala; Ketan Shevde; Peter S Heeger; Ming Zhang
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 6.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.